BR112022016232A2 - Proteínas biespecíficas anti-her2 manipuladas - Google Patents
Proteínas biespecíficas anti-her2 manipuladasInfo
- Publication number
- BR112022016232A2 BR112022016232A2 BR112022016232A BR112022016232A BR112022016232A2 BR 112022016232 A2 BR112022016232 A2 BR 112022016232A2 BR 112022016232 A BR112022016232 A BR 112022016232A BR 112022016232 A BR112022016232 A BR 112022016232A BR 112022016232 A2 BR112022016232 A2 BR 112022016232A2
- Authority
- BR
- Brazil
- Prior art keywords
- manipulated
- subdomain
- bispecific anti
- her2
- proteins
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 4
- 108090000623 proteins and genes Proteins 0.000 title abstract 4
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 3
- 102000051957 human ERBB2 Human genes 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 206010027476 Metastases Diseases 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
PROTEÍNAS BIESPECÍFICAS ANTI-HER2 MANIPULADAS. Em um aspecto, são fornecidas proteínas biespecíficas com a capacidade de se ligar especificamente ao subdomínio II de HER2 humano e ao subdomínio IV de HER2 humano. Em outro aspecto, são fornecidos métodos de tratamento de um câncer ou tratamento de metástase cerebral de um câncer usando uma proteína biespecífica que se liga especificamente ao subdomínio II e subdomínio IV de HER2 humano.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062978758P | 2020-02-19 | 2020-02-19 | |
PCT/US2021/018705 WO2021168194A1 (en) | 2020-02-19 | 2021-02-19 | Engineered anti-her2 bispecific proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022016232A2 true BR112022016232A2 (pt) | 2022-11-16 |
Family
ID=77391704
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022016232A BR112022016232A2 (pt) | 2020-02-19 | 2021-02-19 | Proteínas biespecíficas anti-her2 manipuladas |
Country Status (13)
Country | Link |
---|---|
US (1) | US20230192887A1 (pt) |
EP (1) | EP4181950A4 (pt) |
JP (1) | JP2023514371A (pt) |
KR (1) | KR20220156526A (pt) |
CN (1) | CN115361972A (pt) |
AR (1) | AR121384A1 (pt) |
AU (1) | AU2021224200A1 (pt) |
BR (1) | BR112022016232A2 (pt) |
CA (1) | CA3170338A1 (pt) |
IL (1) | IL295729A (pt) |
MX (1) | MX2022010161A (pt) |
TW (1) | TW202144431A (pt) |
WO (1) | WO2021168194A1 (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL307373A (en) | 2017-02-17 | 2023-11-01 | Denali Therapeutics Inc | Polypeptides that bind to a transgenic transferrin receptor |
KR20230086703A (ko) | 2020-10-14 | 2023-06-15 | 데날리 테라퓨틱스 인크. | 설포글루코사민 설포하이드롤라제 효소를 포함하는 융합 단백질 및 이의 방법 |
EP4392064A2 (en) * | 2021-08-25 | 2024-07-03 | Denali Therapeutics Inc. | Engineered anti-her2 bispecific proteins |
WO2024028732A1 (en) * | 2022-08-05 | 2024-02-08 | Janssen Biotech, Inc. | Cd98 binding constructs for treating brain tumors |
WO2024028731A1 (en) * | 2022-08-05 | 2024-02-08 | Janssen Biotech, Inc. | Transferrin receptor binding proteins for treating brain tumors |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6817064B2 (ja) * | 2013-11-27 | 2021-01-20 | ザイムワークス,インコーポレイテッド | Her2を標的とする二重特異性抗原結合性コンストラクト |
MX2016008098A (es) * | 2013-12-20 | 2017-01-11 | Hoffmann La Roche | Anticuerpos biespecificos del receptor 2 de factor de crecimiento ipidermico himano (her2) y metodo de uso. |
BR112016022910A2 (pt) * | 2014-04-11 | 2017-10-17 | Medimmune Llc | anticorpos contra her2 biespecíficos |
KR20230149328A (ko) * | 2014-12-22 | 2023-10-26 | 시스트이뮨, 인코포레이티드 | 이중특이적 4가 항체 및 이의 제조 및 사용방법 |
JP7021955B2 (ja) * | 2015-06-24 | 2022-03-03 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Her2及び血液脳関門受容体に特異的な三重特異性抗体及び使用方法 |
JP2020530465A (ja) * | 2017-08-10 | 2020-10-22 | デナリ セラピューティクス インコーポレイテッドDenali Therapeutics Inc. | トランスフェリン受容体結合タンパク質を使用するための、親和性に基づく方法 |
AU2019326545A1 (en) * | 2018-08-22 | 2021-03-11 | Denali Therapeutics Inc. | Anti-HER2 polypeptides and methods of use thereof |
-
2021
- 2021-02-19 IL IL295729A patent/IL295729A/en unknown
- 2021-02-19 AR ARP210100440A patent/AR121384A1/es unknown
- 2021-02-19 BR BR112022016232A patent/BR112022016232A2/pt unknown
- 2021-02-19 CN CN202180027050.7A patent/CN115361972A/zh active Pending
- 2021-02-19 JP JP2022549653A patent/JP2023514371A/ja active Pending
- 2021-02-19 EP EP21756590.2A patent/EP4181950A4/en active Pending
- 2021-02-19 KR KR1020227028989A patent/KR20220156526A/ko unknown
- 2021-02-19 WO PCT/US2021/018705 patent/WO2021168194A1/en unknown
- 2021-02-19 TW TW110105842A patent/TW202144431A/zh unknown
- 2021-02-19 AU AU2021224200A patent/AU2021224200A1/en active Pending
- 2021-02-19 CA CA3170338A patent/CA3170338A1/en active Pending
- 2021-02-19 MX MX2022010161A patent/MX2022010161A/es unknown
-
2022
- 2022-08-11 US US17/819,182 patent/US20230192887A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2023514371A (ja) | 2023-04-05 |
CA3170338A1 (en) | 2021-08-26 |
KR20220156526A (ko) | 2022-11-25 |
AR121384A1 (es) | 2022-06-01 |
WO2021168194A1 (en) | 2021-08-26 |
MX2022010161A (es) | 2022-11-07 |
AU2021224200A1 (en) | 2022-09-08 |
CN115361972A (zh) | 2022-11-18 |
US20230192887A1 (en) | 2023-06-22 |
EP4181950A4 (en) | 2024-07-17 |
IL295729A (en) | 2022-10-01 |
TW202144431A (zh) | 2021-12-01 |
EP4181950A1 (en) | 2023-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022016232A2 (pt) | Proteínas biespecíficas anti-her2 manipuladas | |
CR20220396A (es) | Anticuerpos y proteínas de fusión que se unen a ccr8 y usos de estos | |
EA201990781A1 (ru) | Анти-steap2 антитела, конъюгаты антитело-лекарственное средство и биспецифические антигенсвязывающие молекулы, которые связывают steap2 и cd3, и их применение | |
MX2023005375A (es) | Anticuerpos trivalentes biespecificos unidos a claudina 6 o claudina 18.2 y cd3 para el tratamiento de enfermedades de cancer que expresan claudina. | |
BR112019005670A2 (pt) | anticorpos anti-muc16 (mucina 16) | |
ZA202005259B (en) | Anti-ctla4 antibodies and methods of making and using the same | |
EA201891084A1 (ru) | Антитела к il1rap, биспецифические антигенсвязывающие молекулы, которые связываются с il1rap и cd3, и их применение | |
BR112018007046A2 (pt) | anticorpo isolado ou fragmento de ligação a antígeno, composição farmacêutica, molécula de polinucleotídeo isolado, vetor, célula, e, métodos para inibir o crescimento de um tumor ou de uma célula tumoral e para tratar uma doença ou distúrbio. | |
PH12020552221A1 (en) | Anti-pd-1 antibodies and uses thereof | |
EA201890513A1 (ru) | Антитела к bcma, биспецифические антигенсвязывающие молекулы, которые связываются с bcma и cd3, и их применение | |
GT201200253A (es) | Proteínas terapéuticas de unión a dll4 | |
BR112019000436A2 (pt) | anticorpos anti-pd-1, método de produção e método de uso dos mesmos | |
EA201791393A3 (ru) | Антитела к erbb3 и их применение | |
CO2019003951A2 (es) | Proteínas de unión a cd123 y composiciones y métodos relacionados | |
NZ594682A (en) | Fully human antibodies specific to cadm1 | |
BR112021008060A2 (pt) | Polipeptídeo, anticorpo anti-ctla4 ou fragmento de anticorpo, imunoconjugado, composição farmacêutica, dose única de composição farmacêutica, método de tratar câncer, e, kit para diagnóstico ou tratamento | |
BR112019023909A2 (pt) | método para tratamento de um paciente com câncer de ovário, câncer peritoneal ou câncer de trompa de falópio. | |
BR112021018632A2 (pt) | Moléculas de ligação ao cd3 | |
CO2021011944A2 (es) | Anticuerpos de cd33 y métodos para usar los mismos para tratar el cáncer | |
EA201791691A1 (ru) | ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d | |
MX2021003673A (es) | Anticuerpos anti-vsig4 humano y usos de los mismos. | |
BR112022023117A2 (pt) | Constructos de anticorpos de domínio único neutralizantes de sars-cov2 | |
BR112022021065A2 (pt) | Anticorpos terapêuticos de musk | |
BR112021010634A2 (pt) | Anticorpos antiperiostina e usos dos mesmos | |
BR112023017556A2 (pt) | Anticorpo contra nkp46 e aplicação do mesmo |